- J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldJohnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins th…Endpoints · 1mo ago↗ source
- GSK inks multi-target pact with Engitix; Sangamo considers strategic optionsPlus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ident…Endpoints · 1mo ago↗ source
- Tango plans Phase 3 pancreatic cancer study after combo successWill 2026 be remembered as the year when pancreatic cancer finally became treatable? Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting las…